Perth-based biotechnology comapny pSivida Ltd has signed a $33.7 million agreement with an unnamed investment fund to finance development of the company's diabetic macular edema treatment.

 

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

(first time users)
FREE: 8 articles per month + twice daily business email alerts